-
ATS-9R Workflow for Adipose Gene Silencing
2026-09-28
ATS-9R offers a non-viral route for testing gene silencing in white adipose tissue, including macrophage-focused studies of CCL2 and metabolic inflammation. This workflow connects formulation and delivery checks to practical readouts for obesity-associated inflammation and insulin resistance research.
-
Farnesylation-Driven KRAS Condensates in Colon Cancer
2026-09-27
A 2026 Cell study links farnesylation at KRAS C185 to cytoplasmic condensate formation, RCE1 clustering, and KRAS processing, identifying a regulatory step that supports colon tumor growth. The findings also suggest that disrupting this process with statins may suppress tumor growth and improve response to KRAS G12C inhibition, although further work is needed to define clinical scope and treatment parameters.
-
TBXA2R–ERM Signaling Drives TNBC Metastasis
2026-09-26
The study identifies TBXA2R as a GPCR that activates ezrin, radixin, and moesin through G-protein, Rho GTPase, and kinase signaling, promoting triple-negative breast cancer cell motility and invasion. Its findings connect ERM activation to metastatic colonization in vivo while highlighting the need to distinguish this pathway-specific mechanism from broad kinase perturbation.
-
JZL184: A MAGL Inhibitor for Endocannabinoid Studies
2026-09-26
Use JZL184 to probe how monoacylglycerol lipase inhibition changes 2-AG signaling, then connect those changes to CB1-dependent synaptic and astrocyte readouts. A practical workflow separates the compound’s upstream effect on 2-AG from receptor-level mechanisms, with controls and handling advice for interpreting brain-injury experiments.
-
Lapatinib Beyond HER2: A Receptor-Aware Strategy
2026-09-25
Lapatinib (GW572016) offers a well-defined way to interrogate EGFR and HER2 kinase signaling—but interpreting its effects requires more than a phenotype readout. This article connects receptor-defined experiments with emerging HER2-negative breast cancer findings, outlining an evidence-led path from target engagement to translational hypotheses.
-
Cre Recombinase mRNA as a Delivery-System Probe
2026-09-25
EZ Cap™ Cre mRNA (m1Ψ) can help researchers separate mRNA delivery performance from the biological effect of transient Cre expression. This article connects Cre-based assay design with emerging extrahepatic delivery research and explains what the evidence does—and does not—support.
-
Annexin V-FITC/7-AAD Apoptosis Kit Guide
2026-09-24
The Annexin V-FITC/7-AAD Apoptosis Kit helps distinguish cells with exposed phosphatidylserine from cells whose membranes have become permeable, supporting fluorescence-based cell viability and cytotoxicity assays. It is intended for apoptosis and necrosis detection by flow cytometry or microscopy, not for identifying a specific death pathway or resolving atypical cell-death subtypes.
-
L1023 Anti-Cancer Compound Library for ccRCC Screens
2026-09-24
Use a 1,164-compound, pathway-focused collection to identify cellular phenotypes and prioritize follow-up experiments—not to assume a hit’s mechanism. A PLAC1 study in clear cell renal cell carcinoma offers a practical example of linking target expression, perturbation, and compound response.
-
KNUCKLES Controls Floral Meristem Termination
2026-09-23
This Arabidopsis study identifies KNUCKLES as a transcriptional and epigenetic coordinator of floral meristem termination. By repressing PIN1 and IPT7 through H3K27me3-associated control, KNU connects auxin distribution and cytokinin activity with the WUS–CLV3 stem-cell circuit that determines floral meristem fate.
-
JZL184: From 2-AG Biology to Translation
2026-09-23
JZL184 is more than a pharmacological switch for cannabinoid biology: it is a strategic tool for testing how 2-AG availability, CB1 signaling, astrocytic GLT-1 regulation, pain, and traumatic brain injury outcomes intersect. This article presents a time-resolved, mechanism-first framework for translational research.
-
CP-673451: Selective PDGFRα/β Workflows
2026-09-22
CP-673451 enables selective interrogation of PDGFRα/β signaling, receptor phosphorylation, and PDGF-BB-driven angiogenesis with less kinase-pathway noise than broad RTK inhibitors. This guide translates its nanomolar activity into practical cell-based, angiogenesis, ATRX-aware glioma, and xenograft workflows.
-
Thapsigargin: From Ca2+ Pulse to ER-Stress Assay
2026-09-21
Thapsigargin is a benchmark SERCA pump inhibitor, but its greatest value is as a time-resolved tool for separating calcium signaling from downstream endoplasmic reticulum stress and inflammatory phenotypes. This guide translates mechanistic evidence into assay design decisions, with particular attention to pulmonary inflammation, apoptosis, and model limitations.
-
Phytol Workflows for RXR Signaling and Assay Design
2026-09-21
Phytol supports practical studies of retinoid X receptor signaling while also requiring careful control of hydrophobic formulation, isomer content, metabolism, and GABAergic effects. This guide combines cell-based workflow design with a bounded translation of polymer self-assembly principles to improve assay reproducibility.
-
Abiraterone Acetate in Patient-Derived 3D Models
2026-09-20
A translational framework for using Abiraterone acetate as a CYP17 inhibitor in patient-derived prostate spheroids, with emphasis on mechanism, model context, formulation, and interpretation of discordant drug responses.
-
DCFH-DA for Copper-Driven Macrophage ROS
2026-09-19
Learn how to use 2,7-Dichlorodihydrofluorescein diacetate to connect copper handling with oxidative signaling in Ly6C macrophages. This workflow separates intracellular ROS measurement from cell identity, viability, and disease-mechanism controls for more defensible ulcerative colitis research.